Ghrelin as a novel therapy for radiation combined injury

Mol Med. 2010 Mar;16(3-4):137-43. doi: 10.2119/molmed.2009.00154. Epub 2010 Jan 19.

Abstract

The threat of nuclear terrorism has led to growing worldwide concern about exposure to radiation. Acute radiation syndrome, or radiation sickness, develops after whole-body or a partial-body irradiation with a high dose of radiation. In the terrorist radiation exposure scenario, however, radiation victims likely suffer from additional injuries such as trauma, burns, wounds or sepsis. Thus, high-dose radiation injuries and appropriate therapeutic interventions must be studied. Despite advances in our understanding of the pathophysiology of radiation injury, very little information is available on the therapeutic approaches to radiation combined injury. In this review, we describe briefly the pathological consequences of ionizing radiation and provide an overview of the animal models of radiation combined injury. We highlight the combined radiation and sepsis model we recently established and suggest the use of ghrelin, a novel gastrointestinal hormone, as a potential therapy for radiation combined injury.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Disease Models, Animal*
  • Ghrelin / therapeutic use*
  • Humans
  • Mice
  • Radiation Injuries, Experimental / drug therapy*
  • Radiation Injuries, Experimental / pathology*
  • Radiation, Ionizing
  • Rats
  • Sepsis / etiology

Substances

  • Ghrelin